Stability study of Prulifloxacin and Ulifloxacin in human plasma by HPLC–DAD

References

• Rafailidis PI, Polyzos KA, Sgouros K, Falagas ME. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. Int J Antimicrob Agents 2011;37:283–90
   PubMed Web of Science ®Google Scholar
• Keam SJ, Perry CM. Prulifloxacin. Drugs 2004;64:2221–34
   PubMed Web of Science ®Google Scholar
• Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 2006;19:20–9
   PubMed Web of Science ®Google Scholar
• Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881–4
   PubMed Web of Science ®Google Scholar
• Blasi F, Aliberti S, Tarsia P, et al. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. Int J Chron Obstruct Pulmon Dis 2007;2:27–31
   PubMedGoogle Scholar
• Fritsche TR, Biedenbach DJ, Jones RN. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrob Agents Chemother 2009;53:1221–4
   PubMed Web of Science ®Google Scholar
• Paredes-Paredes M, Flores-Figueroa J, DuPont HL. Advances in the treatment of travelers' diarrhea. Curr Gastroenterol Rep 2011;13:402–7
   PubMedGoogle Scholar
• Tougou K, Nakamura A, Watanabe S, et al. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 1998;26:355–9
   PubMed Web of Science ®Google Scholar
• Locatelli M, Melucci D, Carlucci G, Locatelli C. Recent HPLC strategies to improve sensitivity and selectivity for the analysis of complex matrices. Instrum Sci Technol 2012;40:112–37
   Web of Science ®Google Scholar
• Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994;34:930–7
   PubMed Web of Science ®Google Scholar
• Carmignani G, De Rose AF, Olivieri L, et al. Prulifloxacin versus Ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 2005;74:326–31
   PubMed Web of Science ®Google Scholar
• Guo L, Qi M, Jin X, et al. Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography–tandem mass spectrometry. J Chromatogr B 2006;832:280–5
   PubMed Web of Science ®Google Scholar
• Roy B, Choudhury H, Das A, et al. Development and validation of a liquid chromatography–tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study. Biomed Chromatogr 2011;25:890–901
   PubMed Web of Science ®Google Scholar
• Yu F, Dazhai Z, Kangbing W, Fang C. Sensitive determination of Prulifloxacin by its fluorescence enhancement on Terbium (III)-Sodium Dodecylbenzene Sulfonate System. Anal Lett 2008;41:3124–37
   Web of Science ®Google Scholar
• Huang YB, Wang SJ, Zi YQ, et al. Investigation on the interaction of prulifloxacin with human serum albumin: a spectroscopic analysis. Chem Pharm Bull 2010;58:582–6
   PubMed Web of Science ®Google Scholar
• Huang Y, Yan J, Liu B, et al. Investigation on interaction of prulifloxacin with pepsin: a spectroscopic analysis. Spectrochim Acta A 2010;75:1024–9
   Web of Science ®Google Scholar
• Pellegrino RM, Segoloni F, Cagini C. Simultaneous determination of Ciprofloxacin and the active metabolite of Prulifloxacin in aqueous human humor by high-performance liquid chromatography. J Pharmaceut Biomed Anal 2008;47:567–74
   PubMed Web of Science ®Google Scholar
• Locatelli M, Carlucci G. Advanced capillary electrophoresis techniques in the analytical quantification of drugs, metabolites and biomarkers in biological samples. Global J Anal Chem 2010;1:244–61
   Google Scholar
• Zhang L, Wen J, Pan Y, et al. Determination of ulifloxacin, the active metabolite of prulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis. J Chromatogr B 2008;872:172–6
   PubMed Web of Science ®Google Scholar
• Yu F, Liu W, Chen F, Cai P. Highly sensitive spectrofluorimetric determination of trace amounts of prulifloxacin using the aluminium (III)-prulifloxacin system. Luminescence 2008;23:429–33
   PubMed Web of Science ®Google Scholar
• Yu F, Gao Y, Cui M, et al. Fluorescence probe enhanced spectrofluorimetric method for the determination of prulifloxacin in pharmaceutical formulations and biological fluids. Anal Lett 2008;41:2933–43
   Web of Science ®Google Scholar
• Cui M, Yu F, Chen F, Chen L. A direct chemiluminescence method for the determination of prulifloxacin using tris-(4,7-diphenyl-1,10-phenanthrolinedisulfonic acid) ruthenium(II)–cerium(IV) system. Anal Lett 2008;41:2001–12
   Web of Science ®Google Scholar
• Yang Z, Wang X, Qin W, Zhao H. Capillary electrophoresis-chemiluminescence determination of norfloxacin and Prulifloxacin. Anal Chim Acta 2008;623:231–7
   PubMed Web of Science ®Google Scholar
• Locatelli M, Governatori L, Carlucci G, et al. Recent application of analytical methods to phase I and phase II drugs development: a review. Biomed Chromatogr 2012;26:283–300
   PubMed Web of Science ®Google Scholar
• Zaza S, Lucini SM, Sciascia F, et al. Recent advances in the separation and determination of impurities in pharmaceutical products. Instrum Sci Technol. DOI:10.1080/10739149.2014.921792
   Google Scholar
• Locatelli M, De Lutiis F, Carlucci G. High performance liquid chromatography determination of Prulifloxacin and five related impurities in pharmaceutical formulations. J Pharm Biomed Anal 2013;78–79:27–33
   PubMed Web of Science ®Google Scholar
• Locatelli M, Ferrone V, Cifelli R, et al. Microextraction by packed sorbent and HPLC determination of seven non-steroidal anti-inflammatory drugs in human plasma and urine. J Chromatogr A 2014;1367:1–8
   PubMed Web of Science ®Google Scholar
• Pastorini E, Locatelli M, Simoni P, et al. Development and validation of a HPLC–ESI–MS/MS method for the determination of 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid in human plasma. J Chromatogr B 2008;872:99–106
   PubMed Web of Science ®Google Scholar
• Carlucci G, Selvaggi F, Sulpizio S, et al. Combined derivatization and high-performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of Octreotide and Gabexate Mesylate metabolite in human pancreatic juice samples. Biomed Chromatogr. DOI: 10.1002/bmc.3373
   Google Scholar
• CDER and CVM Guidance for Industry, Bioanalytical Method Validation. Food and Drug Administration, May 2001. Available from: http://www.fda.gov/cder/guidance/4252fnl.pdf [last accessed 12 Jan 2015]
   Google Scholar
• International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology, ICH Q2 (R1); 2005. Available from: https://doi.org/http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf [last accessed 12 Jan 2015]
   Google Scholar
• Taverniers I, Van Bockstaele E, De Loose M. Trends in quality in the analytical laboratory. II. Analytical method validation and quality assurance. Trend Anal Chem 2004;23:535–2
   Web of Science ®Google Scholar
• Raju B, Ramesh M, Srinivas R, et al. Identification and characterization of stressed degradation products of prulifloxacin using LC–ESI–MS/Q-TOF, MSn experiments: development of a validated specific stability-indicating LC–MS method. J Pharmaceut Biomed Anal 2011;56:560–8.33
   PubMed Web of Science ®Google Scholar